Dr. Brayer on the Promise of BiTEs in Multiple Myeloma
Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.
Dr. Brayer on the Emergence of BiTEs and Bispecific Antibodies in Multiple Myeloma
Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.
Dr. Brayer on Alternatives to CAR T-Cell Therapy in Multiple Myeloma
Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
2 Clarke Drive Cranbury, NJ 08512